Daiichi’s Anti-Clotting Drug Hit By New U.S. FDA Delay
This article was originally published in PharmAsia News
Daiichi Sankyo's Effient (prasugrel) anti-clotting drug, which it is developing with U.S.-based Eli Lilly, has hit a new snag in obtaining U.S. FDA approval. The agency told the companies it had not completed its review yet, but did not say how much longer it would take. The approval had been expected Sept. 26. The agency already had delayed its review by three months. It provided no additional information. The drug is expected to be a $2 billion-a-year blockbuster for the two. (Click here for more
You may also be interested in...
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.